{"id":7581,"date":"2025-02-15T10:21:00","date_gmt":"2025-02-15T05:21:00","guid":{"rendered":"https:\/\/ksestocks.com\/blog\/?p=7581"},"modified":"2025-02-15T11:59:12","modified_gmt":"2025-02-15T06:59:12","slug":"can-cphl-dominate-pakistans-growing-antibiotic-sector","status":"publish","type":"post","link":"https:\/\/ksestocks.com\/blog\/can-cphl-dominate-pakistans-growing-antibiotic-sector\/","title":{"rendered":"Can CPHL dominate Pakistan\u2019s growing antibiotic sector?"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Key takeaways<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pakistan\u2019s antibiotic market is valued at Rs185 billion, growing <strong>12% YoY in FY25<\/strong>.<\/li>\n\n\n\n<li>CPHL is set to launch four new antibiotics to tap into this high-growth sector.<\/li>\n\n\n\n<li>The new products include Triaxonecit (Ceftriaxone sodium), Floxcip (Ciprofloxacin HCL), Cefask (Cefixime trihydrate), and Lenon (Levofloxacin).<\/li>\n\n\n\n<li>CPHL aims to capture market share in key antibiotic segments, dominated by SAMI, Getz Pharma, and Barrett Hodgson.<\/li>\n\n\n\n<li>These new launches will help strengthen CPHL\u2019s presence in the retail pharmaceutical sector.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">CPHL enters Pakistan\u2019s Rs185 billion antibiotic market<\/h2>\n\n\n\n<p>The Pakistani pharmaceutical industry continues to expand, with the antibiotic segment alone valued at Rs185 billion in FY25. With 12% YoY growth, the sector presents a massive opportunity for pharmaceutical companies looking to expand their market share.<\/p>\n\n\n\n<p>To capture this demand, Citi Pharma Limited (CPHL) is launching <strong>four new antibiotics<\/strong>, strategically targeting high-demand bacterial infections. These include Triaxonecit (Ceftriaxone sodium), Floxcip (Ciprofloxacin HCL), Cefask (Cefixime trihydrate), and Lenon (Levofloxacin).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">CPHL\u2019s new antibiotic portfolio<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">1. Triaxonecit (Ceftriaxone Sodium) \u2013 Targeting Severe Bacterial Infections<\/h3>\n\n\n\n<p>Ceftriaxone sodium is a <strong>widely used antibiotic<\/strong> for treating pneumonia, meningitis, blood infections, and urinary tract infections. The total market size for this molecule is Rs27.5 billion. Among the leading brands, <strong>SAMI\u2019s Oxdil holds a 26% market share<\/strong>, followed by <strong>Macter\u2019s Titan brand with 9%<\/strong>.<\/p>\n\n\n\n<p>By introducing Triaxonecit, CPHL aims to compete with established brands in the injectable antibiotics segment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">2. Floxcip (Ciprofloxacin HCL) \u2013 A Powerful Broad-Spectrum Antibiotic<\/h3>\n\n\n\n<p>Ciprofloxacin is used for severe infections that do not respond to other antibiotics. It is available in pill and intravenous (IV) forms, with a total market size of Rs16 billion.<\/p>\n\n\n\n<p>The segment leader is <strong>SAMI\u2019s Novidat<\/strong>, which dominates the market. With the launch of <strong>Floxcip<\/strong>, CPHL is entering a <strong>high-demand antibiotic category<\/strong> that treats a variety of bacterial infections.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">3. Cefask (Cefixime Trihydrate) \u2013 Fighting Respiratory &amp; Urinary Tract Infections<\/h3>\n\n\n\n<p>Cefixime trihydrate is a widely prescribed antibiotic for ear infections, throat infections, UTIs, and pneumonia. The <strong>total market for this segment is Rs22 billion<\/strong>.<\/p>\n\n\n\n<p>Barrett Hodgson\u2019s Cepsan leads with an 18% market share, while SAMI\u2019s Caricef holds 17%. CPHL\u2019s <strong>Cefask<\/strong> aims to capture a portion of this <strong>high-growth market segment<\/strong>, offering a cost-effective alternative to existing brands.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">4. Lenon (Levofloxacin) \u2013 Targeting Respiratory Infections<\/h3>\n\n\n\n<p>Levofloxacin is a widely used respiratory antibiotic, with a <strong>market size of Rs6 billion<\/strong>. <strong>Getz Pharma\u2019s Leflox leads the segment with a 29% share<\/strong>, followed by <strong>High-Q\u2019s Levo (9%)<\/strong>.<\/p>\n\n\n\n<p>With <strong>Lenon<\/strong>, CPHL is aiming to <strong>expand into the levofloxacin market<\/strong>, leveraging its <strong>retail expansion strategy<\/strong> to compete with leading pharmaceutical brands.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why CPHL\u2019s Antibiotic Expansion Matters<\/h2>\n\n\n\n<p>CPHL\u2019s foray into the <strong>antibiotic market is a strategic move<\/strong> that aligns with its <strong>retail expansion plans<\/strong>. By introducing <strong>widely used, high-demand antibiotics<\/strong>, the company is set to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Strengthen its market position in the retail pharmaceutical segment.<\/li>\n\n\n\n<li>Compete with major players like SAMI, Getz Pharma, and Barrett Hodgson.<\/li>\n\n\n\n<li>Leverage Pakistan\u2019s growing antibiotic demand, fueled by rising bacterial infections and increasing prescriptions.<\/li>\n<\/ul>\n\n\n\n<p>CPHL\u2019s entry into Pakistan\u2019s Rs185 billion antibiotic market is a bold step toward establishing itself in the retail pharmaceutical sector. With the launch of <strong>four key antibiotics<\/strong>, the company is poised to challenge industry leaders and capture a share of this high-growth market.<\/p>\n\n\n\n<p>As CPHL continues to expand its product portfolio, its focus on high-demand therapeutic segments will play a crucial role in driving future growth and profitability.<\/p>\n\n\n\n<p><strong>Source: Sherman Research<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key takeaways CPHL enters Pakistan\u2019s Rs185 billion antibiotic market The Pakistani pharmaceutical industry continues to expand, with the antibiotic segment alone valued at Rs185 billion in FY25. With 12% YoY growth, the sector presents a massive opportunity for pharmaceutical companies looking to expand their market share. To capture this demand, Citi Pharma Limited (CPHL) is [&hellip;]<\/p>\n","protected":false},"author":9252,"featured_media":6638,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[154,155],"tags":[242],"class_list":["post-7581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-analysis","category-fundamental-analysis","tag-cphl"],"featured_image_src":{"landsacpe":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/CPHL-STOCK-PSX-1140x445.png",1140,445,true],"list":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/CPHL-STOCK-PSX-463x348.png",463,348,true],"medium":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/CPHL-STOCK-PSX-300x188.png",300,188,true],"full":["https:\/\/ksestocks.com\/blog\/wp-content\/uploads\/2024\/11\/CPHL-STOCK-PSX.png",1920,1200,false]},"_links":{"self":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/7581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/users\/9252"}],"replies":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/comments?post=7581"}],"version-history":[{"count":0,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/posts\/7581\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media\/6638"}],"wp:attachment":[{"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/media?parent=7581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/categories?post=7581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ksestocks.com\/blog\/wp-json\/wp\/v2\/tags?post=7581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}